scholarly journals Double Perforation after Colorectal Cancer Surgery During Bevacizumab Treatment

2020 ◽  
Vol 27 (4) ◽  
pp. 309-312
Author(s):  
Lucian Sorin ANDREI ◽  
Radu Sorin POPISTEANU ◽  
Adriana ANDREI ◽  
Alexandru MICU ◽  
Ioana DINU
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibody ◽  
Vascular Endothelial Growth Factor ◽  
Small Intestine ◽  
Colorectal Anastomosis ◽  
Vascular Endothelial ◽  
Colorectal Cancer Surgery ◽  
Bevacizumab Treatment ◽  
Endothelial Growth Factor ◽  
Metastasized Colorectal Cancer

Bevacizumab is a monoclonal antibody which has shown promising results in the treatment of varied malignant pathology, including metastasized colorectal cancer. It acts by inhibiting VEGF (vascular endothelial growth factor), and one of its most cited complications is intestinal perforation, by mechanisms which are not yet fully understood. We present the case of a 68 year old patient, operated for metastasized colorectal cancer, which underwent chemotherapy with Bevacizumab, and shortly after initiating therapy developed fi stula of low colorectal anastomosis, followed by ischemic perforation of the small intestine.

Expression of Vascular Endothelial Growth Factor in Colorectal Cancer

2008 ◽  
Vol 24 (6) ◽  
pp. 433
Author(s):  
Tai-woong Jo ◽  
Sung-Chul Lim ◽  
Sungsoo Kim ◽  
Young-Don Min ◽  
Kyung-Jong Kim
Keyword(s):  
Colorectal Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

A novel approach for the discrimination of culture medium from Vascular Endothelial Growth Factor (VEGF) overexpressing colorectal cancer cells

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Sinem Tunçer ◽  
Rafig Gurbanov
Keyword(s):  
Colorectal Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Ftir Spectroscopy ◽  
Cancer Cells ◽  
Lower Amount ◽  
Vascular Endothelial ◽  
Colorectal Cancer Cells ◽  
Endothelial Growth Factor

AbstractObjectivesThe expression level of Vascular Endothelial Growth Factor (VEGF) is assumed as a prognostic marker for several tumor types, including colorectal cancer. Therefore, the determination of pre- and post-therapy levels of VEGF appears to have great value in the assessment of tumor prognosis. Enzyme-Linked Immunosorbent Assay (ELISA) is commonly used for the determination of serum or plasma VEGF levels, but the method is costly and time-consuming. In this study, we aimed to describe a rapid and cost-effective analysis method to discriminate VEGF overexpressing colorectal cancer-derived conditioned medium (CM).MethodsAttenuated Total Reflection (ATR)-Fourier Transform Infrared (FTIR) spectroscopy, combined with Principal Component Analysis (PCA) and Linear Discriminant Analysis (LDA), was used to differentiate VEGF overexpressing colorectal cancer cell line CM from CM obtained from the corresponding control cells which express and secrete relatively lower amount of VEGF.ResultsSamples belong to VEGF overexpressing colorectal cancer cells were clearly distinguished from the control group with very high PC scores as PC1 + PC2 = 96%. Besides, a 100% accurate distinction between these two groups was achieved by the LDA analysis.ConclusionsATR-FTIR spectroscopy combined with pattern recognition techniques was able to discriminate CM of VEGF overexpressing colorectal cancer cells with high efficiency and accuracy.

Sign in / Sign up

Export Citation Format

Share Document